New Colombia Resources, Inc., a U.S.-based company with assets in Colombia, plans to gain approval to legally research and market cannabis-based pharmaceutical products in Colombia and other Latin American countries. As part of that effort, the company has announced the appointment of Dr. Robert J. Melamede, Ph.D., president of Cannabis Science, Inc., as a scientific advisor.
Dr. Melamede, retired chairman of the biology department at the University of Colorado and Colorado Springs, is a world renowned cannabis researcher who has spent years investigating the human endocannabinoid system.
"I am thrilled to finally start this project in Colombia given its history and rising economic standing on the world stage," Melamede said. "Many patients in Latin America will benefit from the research done in Colombia."
New Colombia Resources plans to form a joint venture to include U.S. and Colombian investors, universities, and pharmaceutical partners. The company is also exploring a future collaborative effort with Cannabis Science, Inc.
The company, in a prepared statement, said it will work closely with government agencies to get permission to conduct research on cannabis based formulations, and plans to hire a law firm to handle government approvals, lobbying, and public relations.
The joint venture will conduct studies in different regions of Colombia with high incidences of the specific illnesses for which treatment is being researched, without regard to socioeconomic status, according to New Colombia Resources.